KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Tax Provisions: 2016-2024

Historic Tax Provisions for Halozyme Therapeutics (HALO) over the last 9 years, with Dec 2024 value amounting to $113.0 million.

  • Halozyme Therapeutics' Tax Provisions rose 55.43% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.5 million, marking a year-over-year increase of 71.72%. This contributed to the annual value of $113.0 million for FY2024, which is 69.39% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Tax Provisions stood at $113.0 million for FY2024, which was up 69.39% from $66.7 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Tax Provisions registered a high of $113.0 million during FY2024, and its lowest value of -$154.2 million during FY2021.
  • For the 3-year period, Halozyme Therapeutics' Tax Provisions averaged around $75.5 million, with its median value being $66.7 million (2023).
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 2,072.73% in 2020, then crashed by 71,156.22% in 2021.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Tax Provisions stood at $217,000 in 2020, then slumped by 71,156.22% to -$154.2 million in 2021, then spiked by 130.34% to $46.8 million in 2022, then surged by 42.63% to $66.7 million in 2023, then soared by 69.39% to $113.0 million in 2024.